MHRA’s Rawlins Says New Approach Needed For Clinical Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
The chairman of Britain’s regulator the MHRA says clinical trials need more adaptive designs using smaller patient numbers if drug development costs are to be cut and innovative therapies made more accessible more quickly.